Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model

被引：0
|
作者：
Beibei Luo
Bo Li
Wenke Wang
Xiangjuan Liu
Xiaoman Liu
Yanfei Xia
Cheng Zhang
Yun Zhang
Mingxiang Zhang
Fengshuang An
机构：
[1] Shandong University Qilu Hospital,The Key Laboratory of Cardiovascular Remodeling and Function Research, Chinese Ministry of Education and Chinese Ministry of Health
来源：
Cardiovascular Drugs and Therapy | 2014年 / 28卷
关键词：
DCM; Rosuvastatin; NLRP3 inflammasome; Gene silencing; MAPKs;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：33 / 43
页数：10
相关论文
共 50 条
  • [1] Rosuvastatin Alleviates Diabetic Cardiomyopathy by Inhibiting NLRP3 Inflammasome and MAPK Pathways in a Type 2 Diabetes Rat Model
    Luo, Beibei
    Li, Bo
    Wang, Wenke
    Liu, Xiangjuan
    Liu, Xiaoman
    Xia, Yanfei
    Zhang, Cheng
    Zhang, Yun
    Zhang, Mingxiang
    An, Fengshuang
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (01) : 33 - 43
  • [2] The NLRP3 Inflammasome and Diabetic CardiomyopathyEditorial to: “Rosuvastatin alleviates diabetic cardiomyopathy by inhibiting NLRP3 inflammasome and MAPK pathways in a type 2 diabetes rat model” by Beibei Luo et al.
    Lalit P. Singh
    Cardiovascular Drugs and Therapy, 2014, 28 (1) : 5 - 6
  • [3] Coriolus versicolor alleviates diabetic cardiomyopathy by inhibiting cardiac fibrosis and NLRP3 inflammasome activation
    Wang, Yueqiu
    Li, Hui
    Li, Yang
    Zhao, Yihan
    Xiong, Fangfei
    Liu, Yining
    Xue, Hongru
    Yang, Zhenyu
    Ni, Sha
    Sahil, Abbas
    Che, Hui
    Wang, Lihong
    PHYTOTHERAPY RESEARCH, 2019, 33 (10) : 2737 - 2748
  • [4] NLRP3 Gene Silencing Ameliorates Diabetic Cardiomyopathy in a Type 2 Diabetes Rat Model
    Luo, Beibei
    Li, Bo
    Wang, Wenke
    Liu, Xiangjuan
    Xia, Yanfei
    Zhang, Cheng
    Zhang, Mingxiang
    Zhang, Yun
    An, Fengshuang
    PLOS ONE, 2014, 9 (08):
  • [5] The NLRP3 Inflammasome and Diabetic Cardiomyopathy
    Singh, Lalit P.
    CARDIOVASCULAR DRUGS AND THERAPY, 2014, 28 (01) : 5 - 6
  • [6] Teneligliptin mitigates diabetic cardiomyopathy by inhibiting activation of the NLRP3 inflammasome
    Zhang, Gu-Lao
    Liu, Yuan
    Liu, Yan-Feng
    Huang, Xian-Tao
    Tao, Yu
    Chen, Zhen-Huan
    Lai, Heng-Li
    WORLD JOURNAL OF DIABETES, 2024, 15 (04)
  • [7] Cathelicidin-WA ameliorates diabetic cardiomyopathy by inhibiting the NLRP3 inflammasome
    Peng, Meng
    Liu, Yuan
    Xu, Yawei
    Li, Li
    Li, Yan
    Yang, Haibo
    CELL CYCLE, 2021, 20 (21) : 2278 - 2290
  • [8] NLRP3 Inflammasome as a Molecular Marker in Diabetic Cardiomyopathy
    Luo, Beibei
    Huang, Feng
    Liu, Yanli
    Liang, Yiying
    Wei, Zhe
    Ke, Honghong
    Zeng, Zhiyu
    Huang, Weiqiang
    He, Yan
    FRONTIERS IN PHYSIOLOGY, 2017, 8
  • [9] NLRP3 Inflammasome in Diabetic Cardiomyopathy and Exercise Intervention
    Sun, Yi
    Ding, Shuzhe
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2021, 22 (24)
  • [10] Rutin alleviates diabetic cardiomyopathy in a rat model of type 2 diabetes
    Wang, Yong-Bin
    Ge, Zhi-Ming
    Kang, Wei-Qiang
    Lian, Zhe-Xun
    Yao, Jian
    Zhou, Chang-Yong
    EXPERIMENTAL AND THERAPEUTIC MEDICINE, 2015, 9 (02) : 451 - 455
12345